Results 151 to 160 of about 47,298 (270)

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni, Ebba Qviberg, Edward Chaloner, Hayley Lavender, Maisem Laabei   +4 more
wiley   +1 more source

Myasthenia Gravis (abstract)

, 2017
Myasthenia gravis is a disorder of neuromuscular transmission resulting from binding of autoantibodies to various components of the neuromuscular junction.
Matthew J. Thurtell
core  

Quantitative Muscle MRI of the Lower Extremities Reveals Different Patterns of Involvement in Classic Infantile and Young Late‐Onset Pompe Patients

Journal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.
ABSTRACT With increased survival due to enzyme replacement therapy, children with classic infantile Pompe disease tend to develop a clinical phenotype with pronounced distal muscle weakness, while late‐onset patients typically exhibit proximal muscle weakness.
Jan J. A. van den Dorpel, Mechteld E. Guldemond, Kevin R. Keene, Pieter A. van Doorn, Ans T. van der Ploeg, Johanna M. P. van den Hout, Hermien E. Kan, Nadine A. M. E. van der Beek   +7 more
wiley   +1 more source

Long‐Term Follow‐Up of Patients With Mitochondrial Carbonic Anhydrase VA Deficiency. A Case Report and Literature Review

JIMD Reports, Volume 67, Issue 4, July 2026.
ABSTRACT Mitochondrial carbonic anhydrase VA (CA‐VA) deficiency is a rare inherited metabolic disorder caused by biallelic variants of the CA5A gene. It presents with hyperammonemia, lactic acidosis, and ketonuria, with or without hypoglycemia. We report the long‐term follow‐up of the first two reported cases of CA‐VA deficiency: a 16‐year‐old female ...
Shaymaa Shurrab, Amira Mobarak, Gabriella Horvath, Sylvia Stocker‐Ipsiroglu, Clara van Karnebeek, Ramona Salvarinova‐Zivkovic   +5 more
wiley   +1 more source

Myasthenia Gravis: Recent Developments

, 2005
To: 1. Describe the potential mechanisms for preferential involvement of ocular muscles by myasthenia gravis; 2. Discuss risks and benefits of corticosteroid use for treatment of ocular myasthenia; 3. Appropriately use edrophonium, serum autoantibody and
Henry J. Kaminski, MD
core  

Correction: Identification of potential prognostic biomarkers of thymoma with myasthenia gravis based on serum proteomics

Frontiers in Immunology
Xiaoting Lin, Xiaoting Lin, Xiaoting Lin, Xiaoting Lin, Peng Liu, Peng Liu, Peng Liu, Peng Liu, Guoyan Qi, Guoyan Qi, Guoyan Qi, Guoyan Qi   +11 more
doaj   +1 more source

Digital Phenotyping and Lifestyle Intervention in Patients With Myasthenia Gravis (DIG‐MG): A Randomized Controlled Trial of Feasibility, Adherence, and Effects on Fatigue

Muscle &Nerve, Volume 74, Issue 1, Page 92-102, July 2026.
ABSTRACT Introduction/Aims Physical activity and sleep influence fatigue in myasthenia gravis (MG), and digital health technologies (DHT) enable objective monitoring of these behaviors in daily life. Using this approach, we evaluated whether a lifestyle intervention targeting physical activity or sleep hygiene could reduce fatigue in MG.
Maja Norling, Niclas Eriksson, Elisabet Westerberg, Ingela Nygren, Klara Norman, Julia Hedberg, Sui H. Wong, Susanna Jernelöv, Pernilla Åsenlöf, Anna Rostedt Punga   +9 more
wiley   +1 more source

Telitacicept in refractory juvenile generalized myasthenia gravis: a case report and collective analysis. [PDF]

Front Immunol
Sun Y, Liu G, Zhang H, Ma K.
europepmc   +1 more source

Impact of Thyroid Transcription Factor‐1 Expression on Outcomes of Platinum‐Based Chemoimmunotherapy in Advanced or Recurrent Non‐Squamous Non‐Small Cell Lung Cancer

Thoracic Cancer, Volume 17, Issue 13, July 2026.
Among thyroid transcription factor‐1 (TTF‐1) negative non‐squamous (non‐sq) NSCLC patients, platinum and pemetrexed plus pembrolizumab showed comparable and preferable efficacy in terms of progression‐free survival and overall survival to that observed in TTF‐1‐positive patients.
Ryohei Kamada, Hiroshi Yokouchi, Shohei Mizobuchi, Ken Kuwahara, Yasushi Mizukami, Hidenori Mizugaki, Noriyuki Yamada, Hajime Asahina, Hirofumi Adachi, Yoshihiro Matsuno, Satoshi Oizumi   +10 more
wiley   +1 more source

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT). [PDF]

J Neurol
Howard JF, Saccà F, Hoffmann S, Attarian S, De Bleecker JL, Beauchamp J, Brauer E, Kerstens R, Vissing J, Meisel A, ADAPT Study Group.   +10 more
europepmc   +1 more source